Why the Cardiex (ASX:CDX) share price, up 73% in 2020, is gaining again today

The CardieX share price is up 73% so far in 2020. And it’s up another 2% in afternoon trading. We take a look at why..
The post Why the Cardiex (ASX:CDX) share price, up 73% in 2020, is gaining again today appeared first on The Motley Fool Australia. –

heart shaped balloons flying in the air representing Cardiex share price

The Cardiex Ltd (ASX: CDX) share price is up 3.9% to 5.3 cents in afternoon trading after the company released a positive update on its half year sales.

The rise comes as the wider All Ordinaries Index (ASX: XAO) is slipping, down 0.2% to 6884 points.

What’s driving the CardieX share price higher?

In its half year sales and corporate update, CardieX revealed it had achieved record sales for the first half of the 2021 financial year. This puts the health technology company in a position to post a 30% increase in sales compared to H1 FY2020. It’s also the strongest first half results the company has posted in 5 years.

The company attributed the strong sales growth to continuing strength in sales to the research market along with new clinical trial contracts with Bayer AG (announced on 20 August).

In a forward-looking statement, CardieX CEO Craig Cooper said:

I expect this strength to continue into next year given the current pipeline of research sales and new clinical trials in process. With widespread vaccine distribution about to commence, I also expect sales to our traditional clinician market to recover strongly as the US comes out of continuing lock-downs and stay-at-home orders.

In an update to the company’s previously announced share purchase plan (SPP), Cooper said:

We’re targeting to raise $1.0 million under the SPP, however we may decide in our absolute discretion to close the SPP early, scale back applications, or accept an amount above or below the $1.0 million target depending on the level of demand received. We’re expecting to close the SPP on Thursday, 31 December 2020.

CardieX also announced the appointment of Steven Kesten as its new chief medical officer and Mark Gorelick as its new chief product officer.

Company snapshot

CardieX is a global health technology company focused on vascular health issues. Its AtCor Medical division develops medical devices for measuring arterial stiffness and central blood pressure waveforms.

After falling for most of the previous 5 years, the CardieX share price has turned around in 2020. Despite dropping 66% during the wider COVID-19 market rout in February and March, CardieX shares are up 73% year-to-date. And up an impressive 420% from the 25 March lows.

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of June 30th

More reading

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Why the Cardiex (ASX:CDX) share price, up 73% in 2020, is gaining again today appeared first on The Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!